859 related articles for article (PubMed ID: 31612351)
1. Cardiac Protection after Systemic Transplant of Dystrophin Expressing Chimeric (DEC) Cells to the mdx Mouse Model of Duchenne Muscular Dystrophy.
Siemionow M; Malik M; Langa P; Cwykiel J; Brodowska S; Heydemann A
Stem Cell Rev Rep; 2019 Dec; 15(6):827-841. PubMed ID: 31612351
[TBL] [Abstract][Full Text] [Related]
2. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
4. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
[TBL] [Abstract][Full Text] [Related]
5. Intraosseous transplant of dystrophin expressing chimeric (DEC) cells improves skeletal muscle function in
Malik M; Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Postepy Kardiol Interwencyjnej; 2022 Dec; 18(4):399-406. PubMed ID: 36967847
[TBL] [Abstract][Full Text] [Related]
6. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
[TBL] [Abstract][Full Text] [Related]
7. Dystrophin Expressing Chimeric (DEC) Human Cells Provide a Potential Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia J; Marchese E; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Jun; 14(3):370-384. PubMed ID: 29546607
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model.
Siemionow M; Brodowska S; Langa P; Zalants K; Kozlowska K; Grau-Kazmierczak W; Heydemann A
Arch Immunol Ther Exp (Warsz); 2022 Aug; 70(1):20. PubMed ID: 35978142
[TBL] [Abstract][Full Text] [Related]
9. Injection of vessel-derived stem cells prevents dilated cardiomyopathy and promotes angiogenesis and endogenous cardiac stem cell proliferation in mdx/utrn-/- but not aged mdx mouse models for duchenne muscular dystrophy.
Chun JL; O'Brien R; Song MH; Wondrasch BF; Berry SE
Stem Cells Transl Med; 2013 Jan; 2(1):68-80. PubMed ID: 23283493
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model.
Siemionow M; Budzynska K; Zalants K; Langa P; Brodowska S; Siemionow K; Heydemann A
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540201
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Cell Therapies as a Novel Approach for Duchenne Muscular Dystrophy (DMD) and Muscle Regeneration.
Budzynska K; Siemionow M; Stawarz K; Chambily L; Siemionow K
Biomolecules; 2024 May; 14(5):. PubMed ID: 38785982
[TBL] [Abstract][Full Text] [Related]
12. Placenta-derived mesenchymal stromal cells and their exosomes exert therapeutic effects in Duchenne muscular dystrophy.
Bier A; Berenstein P; Kronfeld N; Morgoulis D; Ziv-Av A; Goldstein H; Kazimirsky G; Cazacu S; Meir R; Popovtzer R; Dori A; Brodie C
Biomaterials; 2018 Aug; 174():67-78. PubMed ID: 29783118
[TBL] [Abstract][Full Text] [Related]
13. Peptide-conjugated phosphodiamidate oligomer-mediated exon skipping has benefits for cardiac function in mdx and Cmah-/-mdx mouse models of Duchenne muscular dystrophy.
Blain AM; Greally E; McClorey G; Manzano R; Betts CA; Godfrey C; O'Donovan L; Coursindel T; Gait MJ; Wood MJ; MacGowan GA; Straub VW
PLoS One; 2018; 13(6):e0198897. PubMed ID: 29912990
[TBL] [Abstract][Full Text] [Related]
14. Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up.
Heydemann A; Bieganski G; Wachowiak J; Czarnota J; Niezgoda A; Siemionow K; Ziemiecka A; Sikorska MH; Bozyk K; Tullius SG; Siemionow M
Stem Cell Rev Rep; 2023 Jul; 19(5):1340-1359. PubMed ID: 37000376
[TBL] [Abstract][Full Text] [Related]
15. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
[TBL] [Abstract][Full Text] [Related]
16. Exosome-Derived Dystrophin from Allograft Myogenic Progenitors Improves Cardiac Function in Duchenne Muscular Dystrophic Mice.
Su X; Jin Y; Shen Y; Ju C; Cai J; Liu Y; Kim IM; Wang Y; Yu H; Weintraub NL; Jiang M; Tang Y
J Cardiovasc Transl Res; 2018 Oct; 11(5):412-419. PubMed ID: 30155598
[TBL] [Abstract][Full Text] [Related]
17. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
Betts CA; McClorey G; Healicon R; Hammond SM; Manzano R; Muses S; Ball V; Godfrey C; Merritt TM; van Westering T; O'Donovan L; Wells KE; Gait MJ; Wells DJ; Tyler D; Wood MJ
Hum Mol Genet; 2019 Feb; 28(3):396-406. PubMed ID: 30281092
[TBL] [Abstract][Full Text] [Related]
18. Why is early-onset atrial fibrillation uncommon in patients with Duchenne muscular dystrophy? Insights from the mdx mouse.
Nguyen MN; Hooper C; Stefanini M; Vrellaku B; Carnicer R; Wood MJ; Simon JN; Casadei B
Cardiovasc Res; 2024 Apr; 120(5):519-530. PubMed ID: 38270932
[TBL] [Abstract][Full Text] [Related]
19. Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.
Betts CA; Saleh AF; Carr CA; Hammond SM; Coenen-Stass AM; Godfrey C; McClorey G; Varela MA; Roberts TC; Clarke K; Gait MJ; Wood MJ
Sci Rep; 2015 Mar; 5():8986. PubMed ID: 25758104
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy.
Nitahara-Kasahara Y; Nakayama S; Kimura K; Yamaguchi S; Kakiuchi Y; Nito C; Hayashi M; Nakaishi T; Ueda Y; Okada T
Stem Cell Res Ther; 2023 Apr; 14(1):108. PubMed ID: 37106393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
